Chemomab Therapeutics (CMMB)
(Real Time Quote from BATS)
$0.98 USD
-0.02 (-2.00%)
Updated Aug 5, 2025 03:04 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMMB 0.98 -0.02(-2.00%)
Will CMMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMMB
KURA Stock Rises More Than 15% This Past Week: Here's Why
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Other News for CMMB
Chemomab Therapeutics management to meet with Maxim
CMMB: Upcoming Meeting Hosted by Maxim on August 7-8
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)
CMMB Advances Toward Phase 3 with FDA Approval on Key Milestones | CMMB Stock News